Fig. 2
From: Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Mechanism of action of Rova-T. A Binding of Rova-T to cell surface DLL3 triggers receptor-mediated endocytosis and B internalization of the Rova-T–DLL3 complex followed by fusion with the late endosome. C PBD is released from the Rova-T complex following enzymatic cleavage within the lysosome. The released PBD intercalates between double-stranded nuclear DNA in a site-specific manner and causes DNA damage, which ultimately leads to D apoptosis [17]. ADC antibody-drug conjugate, DLL3 delta-like ligand 3, PBD pyrrolobenzodiazepine, Rova-T rovalpituzumab tesirine